JP2021523151A5 - - Google Patents

Info

Publication number
JP2021523151A5
JP2021523151A5 JP2020562668A JP2020562668A JP2021523151A5 JP 2021523151 A5 JP2021523151 A5 JP 2021523151A5 JP 2020562668 A JP2020562668 A JP 2020562668A JP 2020562668 A JP2020562668 A JP 2020562668A JP 2021523151 A5 JP2021523151 A5 JP 2021523151A5
Authority
JP
Japan
Prior art keywords
solvent
nanoparticles
microparticles
solution
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020562668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031659 external-priority patent/WO2019217780A1/en
Publication of JP2021523151A publication Critical patent/JP2021523151A/ja
Publication of JP2021523151A5 publication Critical patent/JP2021523151A5/ja
Pending legal-status Critical Current

Links

JP2020562668A 2018-05-11 2019-05-10 負の表面電荷を有するマイクロ粒子及びナノ粒子 Pending JP2021523151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670204P 2018-05-11 2018-05-11
US62/670,204 2018-05-11
PCT/US2019/031659 WO2019217780A1 (en) 2018-05-11 2019-05-10 Microparticles and nanoparticles having negative surface charges

Publications (2)

Publication Number Publication Date
JP2021523151A JP2021523151A (ja) 2021-09-02
JP2021523151A5 true JP2021523151A5 (https=) 2022-05-17

Family

ID=68468426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562668A Pending JP2021523151A (ja) 2018-05-11 2019-05-10 負の表面電荷を有するマイクロ粒子及びナノ粒子

Country Status (5)

Country Link
US (1) US20210169819A1 (https=)
EP (1) EP3814272A4 (https=)
JP (1) JP2021523151A (https=)
CA (1) CA3098873A1 (https=)
WO (1) WO2019217780A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210292406A1 (en) * 2020-03-18 2021-09-23 Flow Pharma, Inc. Controlled release of antibodies to modulate cytokines
CA3193188A1 (en) * 2020-10-05 2022-04-14 Cytodigm, Inc. Pharmaceutical composition of siglec-binding agents
CN115382476B (zh) * 2022-07-26 2024-10-22 华东师范大学 一种超小粒径聚合物纳米颗粒的制备方法
EP4572804A2 (en) * 2022-08-17 2025-06-25 The Regents of the University of California Inhalable compositions of cdk9 inhibitors
CN115969796B (zh) * 2022-12-06 2024-07-09 苏州大学 一种jak抑制剂长效微球及其制备方法与应用
WO2025250539A1 (en) * 2024-05-29 2025-12-04 Cytodigm, Inc. Pharmaceutical composition comprising sialic acid for treating diseases related to the lung
CN119033092B (zh) * 2024-10-30 2024-12-24 恢春丹生物科技(海南)有限公司 一种蛹虫草灵芝孢子粉复合制剂及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
HU220357B (hu) 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
AU5732296A (en) 1995-05-08 1996-11-29 Texas Biotechnology Corporation Method for inhibiting the binding of selectins to sialyl-lew ises
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
DE60137728D1 (de) 2000-08-24 2009-04-02 Univ Tennessee Res Foundation Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20030022868A1 (en) 2001-06-25 2003-01-30 Dalton James T. Selective androgen receptor modulators and methods of use thereof
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
AU2002357003A1 (en) 2001-12-28 2003-07-24 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
AU2003217304A1 (en) 2002-02-28 2003-09-16 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
HRP20040818A2 (en) 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
JP2005529952A (ja) 2002-06-17 2005-10-06 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
CA2502209A1 (en) 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
JP4603528B2 (ja) 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
US20040167103A1 (en) 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060258628A1 (en) 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
RU2508093C2 (ru) * 2008-07-01 2014-02-27 Нитто Денко Корпорейшн Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US11607391B2 (en) * 2008-09-25 2023-03-21 Trs Holdings Llc Mineral-coated microspheres
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US9532956B2 (en) * 2009-04-18 2017-01-03 Massachusetts Institute Of Technology PH sensitive biodegradable polymeric particles for drug delivery
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
EP2608809B1 (en) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
AU2011325966B2 (en) * 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
HK1201065A1 (en) 2011-10-04 2015-08-21 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
CN102690399B (zh) 2012-06-14 2013-07-31 太原理工大学 聚天冬氨酸/聚丙烯酸共聚物互穿网络水凝胶及其制备方法
CN110064049B (zh) * 2012-06-21 2024-02-09 西北大学 肽缀合粒子
WO2014047624A1 (en) 2012-09-24 2014-03-27 Gilead Sciences, Inc. Anti-ddr1 antibodies
US11439594B2 (en) * 2012-12-04 2022-09-13 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
PL3008053T3 (pl) 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
JP7194593B2 (ja) * 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子

Similar Documents

Publication Publication Date Title
JP2021523151A5 (https=)
US12605344B2 (en) Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
Kunda et al. Bovine Serum Albumin Adsorbed PGA-co-PDL Nanocarriers for Vaccine Delivery via Dry Powder Inhalation: Kunda et al.
Lassalle et al. PLA nano‐and microparticles for drug delivery: an overview of the methods of preparation
Dinarvand et al. Effect of surfactant HLB and different formulation variables on the properties of poly-D, L-lactide microspheres of naltrexone prepared by double emulsion technique
JP2020125363A (ja) 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
Miladi et al. Particles from preformed polymers as carriers for drug delivery
JP6678571B2 (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
Dhakar et al. Variables influencing the drug entrapment efficiency of microspheres: A pharmaceutical review
Masotti et al. Chitosan micro-and nanospheres: fabrication and applications for drug and DNA delivery
Seremeta et al. Development and characterization of benznidazole nano-and microparticles: a new tool for pediatric treatment of Chagas disease?
CN112972388B (zh) 卡利拉嗪释放制剂
Csaba et al. Design and characterisation of new nanoparticulate polymer blends for drug delivery
JP2022546559A (ja) 櫛形ポリマーおよびブロックコポリマーで安定化された、核酸および他の可溶性親水性化合物を封入するナノ粒子
JP2009542794A (ja) 医薬組成物の調製方法
Rawat et al. Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres
de Almeida Campos et al. Synthesis of polymeric nanoparticles by double emulsion and pH-driven: Encapsulation of antibiotics and natural products for combating Escherichia coli infections
US20220211637A1 (en) Random copolymer stabilized nanoparticles encapsulating soluble hydrophilic compounds
Mustafa et al. Kanamycin Sulphate Loaded PLGA‐Vitamin‐E‐TPGS Long Circulating Nanoparticles Using Combined Coating of PEG and Water‐Soluble Chitosan
CN107106504B (zh) 释放纳米粒子的肠溶微米粒子的制备
JP6121006B2 (ja) 安定剤として生分解性表面活性ブロックコポリマを含むマイクロカプセル化のためのエマルジョン
Chaw et al. Water-soluble betamethasone-loaded poly (lactide-co-glycolide) hollow microparticles as a sustained release dosage form
US20060153923A1 (en) Nanoparticles of polypoxyethylenated derivatives
Park et al. Triptorelin acetate-loaded poly (lactide-co-glycolide)(PLGA) microspheres for controlled drug delivery
CN115942935A (zh) 包括氯胺酮的微球制剂及其制备和使用方法